Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9628555 | 0.91 | SIGMAR1 (0.45) | KDM1ASIGMAR1CYP2C19CYP2C9TSHR | |
| SCHEMBL11077411 | 0.90 | KDM1A (0.57) | KDM1ASIGMAR1CYP2C19CYP3A4 | |
| SCHEMBL988682 | 0.82 | SIGMAR1 (0.44) | KDM1ASIGMAR1CYP2C19CYP2C9TSHR | |
| SCHEMBL30869923 | 0.82 | SIGMAR1 (0.44) | KDM1ASIGMAR1CYP2C19CYP2C9TSHR | |
| SCHEMBL11082282 | 0.81 | CYP3A4 (0.39) | KDM1ACYP2C19CYP3A4POLA1 | |
| SCHEMBL3896827 | 0.80 | SIGMAR1 (0.36) | KDM1ASIGMAR1 | |
| SCHEMBL14857215 | 0.79 | MTNR1A (0.49) | — | |
| SCHEMBL4984411 | 0.78 | POLA1 (0.51) | KDM1ASIGMAR1CYP2C19CYP2C9TSHR | |
| SCHEMBL29587519 | 0.78 | POLA1 (0.51) | KDM1ASIGMAR1CYP2C19CYP2C9TSHR | |
| SCHEMBL4911889 | 0.78 | OPRM1 (0.42) | KDM1ASIGMAR1CYP2C19CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1403256-A1 | FUSED IMIDAZOLE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-0583485-B1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5387710-A | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0583485-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | EP | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
| US-4473586-A | Aminoalkyl dihydronaphthalenes | ABBOTT LABORATORIES (US) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | KDM1A 2636/4885SIGMAR1 1826/4885CYP2C19 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.